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Purpose: Hydromorphone is a potent opioid that may lead to respiratory and central nervous 
system depression prompting naloxone use. The primary objective of this study was to evaluate 
whether a safety initiative implemented at Windsor Regional Hospital involving interchanging 
hydromorphone intravenous or subcutaneous doses of 1 mg or greater to low dose (0.5 mg) in 
opioid naïve, medical and surgical patients was associated with naloxone events. The secondary 
objective was to assess whether there was a compromise in patient pain control with the low 
dose. 
Methods: We conducted a retrospective, multicenter, observational study of medical and 
surgical opioid-naïve patients admitted to Windsor Regional Hospital who received intravenous 
or subcutaneous hydromorphone within an eighteen-month timeframe. To determine if there is 
an association between naloxone events and implementation of the safety initiative, we 
compared patients who experienced a naloxone event (cases) with patients who did not 
experience a naloxone event (controls) in approximately 1:4 ratio. Efficacy outcomes assessed 
changes in patient pain control before and after interchange policy implementation (i.e. need for 
increase in dose, frequency or additional analgesics). 
Results: Of the 4343 patients who received hydromorphone, 143 opioid naïve patients were 
included in the final analysis. Of the 27 patients who experienced a naloxone event, 0% of 
patients were interchanged. In contrast, of the 116 patients who did not experience a naloxone 
event, 52% were interchanged (OR = 0, 95% 0 to 0.13, p<0.01). There were no significant 





Conclusions: The pharmacist-led safety initiative of interchanging all opioid naïve patients to 
low dose hydromorphone was not associated with naloxone events and did not compromise 
patient pain control. 
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Introduction: 
  The Institute of Safe Medication Practices (ISMP) defines opioids as high-alert 
medications because of the potential to cause serious adverse drug events (ADEs) such as 
accidental overdoses and respiratory depression.1 Hydromorphone, a potent opioid, is the most 
common medication voluntarily reported to ISMP Canada for causing patient harm.2 From 
January 2000 to September 2013, ISMP received 233 incidents involving hydromorphone with 
an outcome of harm or death.2   
The hydromorphone package insert suggests a dose of 1-2 mg6; this dose is roughly 
equivalent to 7-14 mg of morphine – an excessive amount for many opioid naïve patients7. 
Several studies have suggested that currently recommended starting doses of hydromorphone or 
the recommended conversions are too high.8-10 Meisenberg et al reduced opioid-induced 
respiratory depression by implementing the use of lower doses of hydromorphone for high-risk 
patients through creating new pain order sets that default to morphine and implementing alerts 
that define opioid naïve when ordering opioids.11 Similarly, Guelst et al. identified that 
hydromorphone was often being prescribed intravenously in excessive doses to opioid-naïve 
patients. Therefore, they re-packaged hydromorphone in 0.2 mg syringes and removed all 2 mg 
vials from patient care units and aggressively educated health care professionals. This 





efficacy through implementing system-related and educational changes over a three-year time 
period.12 
At Windsor Regional Hospital (WRH), there were 86 reported naloxone-related events 
secondary to opioid use from 2016 to 2017.3 The majority of these events were attributed to 
hydromorphone use. Pain guidelines state that patients who are opioid naïve are most at risk of 
opioid-related harm.4-5 These findings prompted the implementation of a safety initiative at 
WRH, whereby pharmacists can interchange all prescribed hydromorphone intravenous or 
subcutaneous doses of 1 mg or greater to low dose (0.5 mg) hydromorphone in opioid naïve 
medical or surgical patients in order to minimize opioid-related adverse effects.  
 We conducted a retrospective, observational study to 1) assess the impact of the policy on 
safety by identifying if there is an association between naloxone events (the outcome) and 
implementation of the interchange (the exposure) and 2) to evaluate efficacy outcomes regarding 
patient pain control with the low dose interchange. We predict that implementation of our 
interchange policy will not be associated with naloxone events and will not compromise patient 
pain control. 
METHODS: 
Selection and Description of Participants 
 A retrospective, case-control study was conducted at two separate hospital sites: Ouellette 
and Metropolitan campus at Windsor Regional Hospital (WRH). This study was approved by the 
WRH Research Ethics Board (REB) #18-345. The computerized pharmacy software (Solcom®, 
WORX, and Horizon’s Medical Manager®, Pyxis® automated dispensing cabinet reports) was 
used to identify all medical and surgical adult patient (≥18 years) admitted to Windsor Regional 





hydromorphone nine months before and after interchange policy implementation. We excluded 
all critically ill patients admitted to the intensive care unit as well as oncology, trauma or 
palliative patients since these patients typically have higher analgesic requirements.  
Data Collection 
 Computerized pharmacy records were used to extract patient and drug data. Specific 
demographic and clinical outcome information was entered into an electronic case report form: 
age, sex, type of patient (i.e. medical or surgical), hospital length of stay and mortality were 
collected. Patient comorbidities that could affect safety and efficacy outcomes including obesity, 
sleep apnea, chronic obstructive pulmonary disease, renal or liver impairment and chronic pain 
were collected. Medication information at baseline and throughout hospital stay including 
benzodiazepine, NSAID, acetaminophen, antidepressant, neuropathic agent or marijuana use at 
baseline and throughout hospital stay was also collected. 
Patients were classified as opioid naïve if they did not have an opioid listed on their 
medication history or filled within the 30 days prior to their hospital admission. Hydromorphone 
prescription information collected included: the dose administered, whether it was interchanged 
to 0.5 mg or less and whether the patient was discharged on hydromorphone or another opioid.   
To evaluate safety outcomes, a report of all the naloxone removals from the Pyxis® 
automated dispensing cabinets with corresponding opioid use was generated. Only naloxone 
administration associated with respiratory depression were included in the analysis. To evaluate 
pain control in all patients who received an interchange to low-dose hydromorphone, the data 
collected included patient hydromorphone requirements such as increase in dose, frequency or 
additional analgesics 24 hours post-interchange. These analgesic requirements were compared 






 For the safety analysis, patients who experienced a naloxone event were categorized as 
cases, and were compared in approximately a 1:4 ratio with patients who did not experience a 
naloxone event as the controls. Continuous variables were reported as means with standard 
deviations or medians with interquartile ranges, which were compared using unpaired T-test and 
Mann Whitney U Test, respectively. Categorical and binary variables were reported as counts 
and percentages and compared using Chi squared test. A p-value of < 0.05 was considered 
statistically significant.   A multivariable regression analysis was conducted in order to identify 
and adjust for any potential confounders. For the safety analysis, there were no naloxone events 
in the intervention arm, therefore the data was un-analyzable with a lower bound of zero and 
upper bound of infinity.  
RESULTS 
Population 
  As shown in Table 1, 143 patients were included in the final analysis. The median age 
was 70 years (IQR=11.3) and 41.9% were female. Twenty-seven patients required naloxone 
administration secondary to respiratory depression 24 hours post-hydromorphone administration. 
These 27 cases were compared with approximately four controls. There were no significant 
differences between cases and controls at baseline in terms of risk factors for respiratory 
depression such as obesity, sleep apnea, chronic obstructive pulmonary disease, renal or liver 
impairment etc. There were no patients receiving non-opioid analgesics in the group that 
experienced a naloxone event in comparison to the control group (0% vs. 30.2%, respectively, 





patients who experienced a naloxone event in comparison to controls (2.2 mg vs. 0.8 mg, p 
<0.001). 
Safety Results 
  Table 2 outlines the association between naloxone events and implementation of 
interchange. Amongst the 27 patients who experienced a naloxone-related event, zero of these 
individuals were interchanged to low dose hydromorphone. In contrast to the group of patients 
that did not result in a naloxone event, 52% of patients were interchanged, indicating a 
statistically significant difference in the implementation of interchange between cases and 
controls (X2 = 27.3, p<0.01).  
Table 3 outlines the naloxone-related events at Windsor Regional Hospital nine months 
before and after the hydromorphone interchange policy was implemented. There was an overall 
24% reduction in naloxone related events post-interchange policy implementation amongst both 
hospital sites (OR = 0.68, 95% CI 0.60-3.82). The Ouellette site demonstrate a 32% reduction 
(OR=0.68, 95% CI: 0.60-3.82) in comparison to the Metropolitan site which showed a 14% 
increase in naloxone-related events (OR= 0.76, 95% CI 0.61 – 2.91). 
Efficacy Results 
  Table 4 outlines the efficacy in pain control in opioid naïve patients before and after the 
hydromorphone interchange policy was implemented.  There were no significant differences in 
need for an increase in dose, frequency or additional analgesics pre vs. post policy 
implementation. There were no differences in concurrent use of other analgesics throughout 
patient hospital stay.  There were significantly less patients being discharged on hydromorphone 






  We determined that the implementation of a pharmacist-led safety initiative whereby 
interchanging all hydromorphone intravenous or subcutaneous doses of 1 mg or greater to low 
dose (0.5 mg) was not associated with naloxone-related events and did not compromise efficacy 
in patient pain control.  
Ricket et al conducted a pilot evaluation of hydromorphone dose substitution on patient 
safety and pain management in a community hospital in Kentucky, USA. The results of this 
study suggest that utilizing lower initial doses of hydromorphone may provide similar efficacy 
for patients who are opioid naïve. Although this pilot study did not achieve adequate statistical 
power, they concluded that initiating low dose hydromorphone in opioid-naïve patients may 
prevent adverse drug events while adequately controlling pain.13 Our study, which implemented 
a similar substitution policy found that substituting to low dose hydromorphone in opioid naïve 
patients was not associated with naloxone events. The patients in the naloxone-event group were 
receiving significantly higher doses of hydromorphone at baseline and none of these patients 
were interchanged. To confirm this implicating factor, the dose of hydromorphone administered 
was the only significant difference found between cases and controls at baseline other than the 
use of non-opioid analgesics. This demonstrates that there was a failure to use a multi-modal 
analgesic approach in order to provide opioid-sparing effects and minimize harm along with 
excessive doses of hydromorphone in the group of patients that experienced a naloxone-related 
event.    
 In terms of efficacy results, there was no difference in patient pain control pre vs. post 
policy implementation, indicating that we can comfortably initiate opioid naïve patients with a 





Doses may be titrated if the patient’s pain is not adequately controlled after the initial dose. 
Furthermore, once our interchange policy was implemented, there were significantly less patients 
being discharged home on hydromorphone post-policy implementation.  This is important 
because multiple studies have reported an increased risk of new persistent opioid use after 
prescription of opioids for acute pain in opioid naïve patients.14-17 Even patients who undergo 
relatively minor low-pain surgery are at increased risk of long-term opioid use.16 
 The strengths of this study include a large number of patients screened who received 
hydromorphone.  We also looked at a variety of possible confounding factors such as obesity, 
sleep apnea, COPD and found no confounders. Furthermore, we implemented an initiative of 
forcing function which is highest on ISMP’s hierarchy of effectiveness2 in achieving safety 
outcomes indicating that the hydromorphone dose cannot be processed without the pharmacist’s 
review. In addition to the safety benefits for patients, this intervention is easy to implement at 
any institution, requires minimal resources, may be cost-saving and may potentially prevent the 
development of opioid use disorder. 
Our study is limited by its retrospective nature since not all interventions were 
documented. Although the order cannot be processed without pharmacist review, the order 
requires pharmacist discretion of whether to interchange. It is possible that not all pharmacists 
were interchanging patients, particularly when the policy was first implemented. Furthermore, 
we used surrogate markers of respiratory depression i.e. naloxone use. Despite this, naloxone is 
the best surrogate marker available since its use is easily captured by the automated pharmacy 
dispensing system. Surrogate markers of pain control were also used because pain scores were 
poorly documented in the charting and would result in incomplete information.  Furthermore, 
pain perception may also vary based on ethnicity and the type of surgery or reason for admission 






We determined that the implementation of a pharmacist-led safety initiative whereby 
interchanging all hydromorphone intravenous or subcutaneous doses of 1 mg or greater to low 
dose was not associated with naloxone-related events and did not compromise efficacy in patient 
pain control. 
Table 1 – Baseline Demographics 
 All Patients  
N = 143 
Naloxone 
Event  
N = 27 
No Naloxone 
Event 
N = 116 
P-value 
Age, years  
(median, IQR) 
70 (11.3) 67 (12.2) 74 (10.3) 0.561 
Sex, female 60 (41.9) 11 (40.7) 49 (42.24) 0.915 
Type of patient     
Medical 59 (41.3) 11 (40.7) 48 (41.4) 0.914 
Surgical 84 (58.7) 16 (59.3) 68 (58.6) 0.914 
Obesity 54 (37.7) 10 (37.0) 44 (37.9) 0.913 
Sleep apnea 12 (8.4) 3 (11.1) 9 (7.8) 0.581 
COPD 21 (14.7) 4 (14.8) 17 (14.7) 0.883 
Renal impairment 25 (17.5) 6 (22.2) 19 (16.4) 0.492 
Liver impairment 7 (4.9) 2 (7.4) 4 (3.4) 0.199 
Chronic pain 28 (19.6) 2 (7.4) 26 (22.4) 0.083 
Benzodiazepine use 22 (15.4) 5 (18.5) 17 (14.7) 0.470 
NSAID/Acetaminophen 












(median, IQR) 6 (8.2) 7 (9.3) 6 (7.8) 
 
0.681 
Death  18 (10.5) 2 (7.4) 16 (13.8) 0.431 
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Table 3- Naloxone Related Events Pre vs. Post Policy Implementation 
  Pre 
(May 2017 to 
Jan 2018) 
Post 
(Feb 2018 to 
Oct 2018) 
OR 
Ouellette Yes 12 8 0.68 (0.60 – 
3.82)  No 1288 1268 
Metropolitan Yes 3 4 1.15 (0.16 – 
4.23)  No 838 975 
Total Yes 15 12 0.76 (0.61 – 
2.91)  No 2111 2232 
 
 
Table 4 – Efficacy Data – Pain Control (Opioid Naïve only) 








N = 82 
(12+70) 
 
























Concurrent use of 
other analgesics 
 
≤1 50 (82) 56 (68) 0.068 
2+ 11 (18) 15 (18) 0.913 
Discharge on 
hydromorphone 
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